VRTX SEC Filings
SEC filings for VRTX. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 8-KAIOn August 27, 2026, Vertex Pharmaceuticals appointed Jonathan Poole, 51, currently SVP Finance, as Executive Vice President and Chief Financial Officer effective January 1, 2027. | Sep 1, 2026 | 0000875320-26-000264EDGAR |
| 8-K | Aug 3, 2026 | 0000875320-26-000256EDGAR |
| 8-K | Jul 7, 2026 | 0001193125-26-296710EDGAR |
| 8-K | May 13, 2026 | 0000875320-26-000204EDGAR |
| 8-K | May 4, 2026 | 0000875320-26-000171EDGAR |
| 8-K | Apr 29, 2026 | 0000875320-26-000166EDGAR |
| 8-KAIVertex Pharmaceuticals completed its rolling Biologics License Application submission to the FDA for potential accelerated approval of povetacicept for IgA nephropathy (IgAN) in adults. | Mar 31, 2026 | 0000875320-26-000147EDGAR |
| 8-K | Feb 12, 2026 | 0000875320-26-000034EDGAR |
| 8-K | Nov 3, 2025 | 0000875320-25-000230EDGAR |
SEC filings for companies related to VRTX
Never miss a VRTX filing.
Get an email when VRTX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.